Evotec
About: Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Employees: 4,766
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
300% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 4
48% more funds holding
Funds holding: 25 [Q1] → 37 (+12) [Q2]
33% more capital invested
Capital invested by funds: $30.4M [Q1] → $40.5M (+$10.1M) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
2.4% less ownership
Funds ownership: 5.12% [Q1] → 2.72% (-2.4%) [Q2]
38% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 8
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
|
HC Wainwright & Co.
Douglas Tsao
|
$7
|
Buy
Maintained
|
14 Aug 2025 |
Financial journalist opinion
